[Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth

• Authors:
  • Zi-Xue Xuan
  • Lin-Na Li
  • Qi Zhang
  • Cheng-Wang Xu
  • De-Xuan Yang
  • Ye Yuan
  • Ying-Hong An
  • Shan-Shan Wang
  • Xiao-Wen Li
  • Shou-Jun Yuan

• View Affiliations

  
  Affiliations: Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China, Department of Production Technology, Shandong Buchang Shenzhou Pharmaceutical Co., Ltd., Heze 274000, P.R. China
• Published online on: October 23, 2023     https://doi.org/10.3892/ijo.2023.5583
• Article Number: 135

• Copyright : © Xuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article

Int J Oncol 45: [Related article:] 2411-2420, 2014; DOI: 10.3892/ijo.2014.2690

Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, for the scratch wound assay experiments shown in Fig. 1 on p. 2413, the panels showing the '0 h' experiments for the respective incubations with VEGF or BC001 were apparently identical.

Figure 1 BC001 inhibits endothelial cells migration. After incubation with BC001, the migrated cells were decreased, compared to that of VEGF(+) group, this result showed BC001 inhibited HUVEC migration. Scale bar, 400 μm.

The authors were able to re-examine their original data files, and realized that this figure had been inadverently assembled incorrectly. The revised version of Fig. 1, containing the correct data for the '0 h / BC001' panel, is shown below. Note that the revisions made to this figure do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of International Journal of Oncology for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused.